McCall Farms recalls Happy Harvest Spinach over mislabeling concerns

McCall Farms recalls Happy Harvest Spinach over mislabeling concerns

Food recall news : McCall Farms, a South Carolina based canned vegetable producer has recalled some cases of Happy Harvest Spinach, its canned spinach product over mislabeling concerns across several US states. Happy Harvest Spinach Food Recall News McCall Farms said that it has recalled limited amount of cases of the canned spinach product in […]

Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities

Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities

Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, Takeda’s fourth attempt to purchase Shire, comes after Shire had previously rejected three offers, citing undervaluation of its business and future growth prospects. Escalation in Acquisition Offers The latest bid […]

Procter & Gamble to acquire Merck’s consumer health business for €3.4bn

Procter & Gamble to acquire Merck’s consumer health business for €3.4bn

Procter & Gamble (P&G), a leading US consumer goods company, has finalized a deal to acquire the consumer health business of German pharmaceutical company Merck for approximately €3.4 billion ($4.2 billion). This all-cash transaction marks a significant expansion of P&G’s consumer health division by incorporating a range of over-the-counter (OTC) products from Merck. Expanding P&G’s […]

Servier Laboratories to acquire Shire’s oncology business for $2.4bn

Servier Laboratories to acquire Shire’s oncology business for $2.4bn

In a strategic move to expand its global presence, French pharmaceutical giant Servier Laboratories has announced a $2.4 billion all-cash acquisition of the oncology business from Irish biotech company Shire. This significant transaction positions Servier to substantially increase its oncology portfolio and establish a direct commercial presence in the United States, the world’s largest biopharmaceutical […]

Sanofi to build new $396m vaccine manufacturing facility in Toronto

Sanofi to build new $396m vaccine manufacturing facility in Toronto

Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine manufacturing facility at its Canadian headquarters, Sanofi Pasteur, in Toronto. This development is aimed at bolstering the company’s operational capabilities in Canada and reaffirming its commitment to advancing global public […]

Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855m to enhance rare disease treatment options

Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855m to enhance rare disease treatment options

In a significant move to expand its rare disease drug portfolio, U.S.-based Alexion Pharmaceuticals has announced an all-cash acquisition of Swedish pharmaceutical company Wilson Therapeutics for SEK7.1 billion ($855 million). This strategic acquisition is set to significantly bolster Alexion’s offerings in the rare disease sector, particularly in treating Wilson disease, a rare copper-mediated disorder. Details […]

Coca-Cola launches Thums Up Charged No Sugar in India

Coca-Cola launches Thums Up Charged No Sugar in India

Soft drinks industry news : Coca-Cola has launched a zero sugar variant of its recently rolled out Thums Up Charged in India, named as Thums Up Charged No Sugar. Coca-Cola’s launch of Thums Up Charged No Sugar is part of its global strategy to provide more choices for its consumers. It can be recalled that […]

GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal

GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal

GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange for a 19.9% equity stake and a seat on Orchard’s board. This move is part of GSK’s strategic initiative to refine its focus on core areas such as respiratory, HIV/infectious […]